Using a rabbit model of tuberculous meningitis, we evaluated the protective efficacy of vaccination with the recombinant polyprotein Mtb72F, which is formulated in two alternative adjuvants, AS02A and AS01B, and compared this to vaccination with Mycobacterium bovis bacillus Calmette-Guérin (BCG) alone or as a BCG prime/Mtb72F-boost regimen. Vaccination with Mtb72F formulated in AS02A (Mtb72F+AS02A) or Mtb72F formulated in AS01B (Mtb72F+AS01B) was protective against central nervous system (CNS) challenge with Mycobacterium tuberculosis H37Rv to an extent comparable to that of vaccination with BCG. Similar accelerated clearances of bacilli from the cerebrospinal fluid, reduced leukocytosis, and less pathology of the brain and lungs were noted. Weight loss of infected rabbits was less extensive for Mtb72F+AS02A-vaccinated rabbits. In addition, protection against M. tuberculosis H37Rv CNS infection afforded by BCG/Mtb72F in a prime-boost strategy was similar to that by BCG alone. Interestingly, Mtb72F+AS01B induced better protection against leukocytosis and weight loss, suggesting that the polyprotein in this adjuvant may boost immunity without exacerbating inflammation in previously BCG-vaccinated individuals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1418915 | PMC |
| http://dx.doi.org/10.1128/IAI.74.4.2392-2401.2006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis.
Iran J Basic Med Sci
June 2020
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Objectives: (), an intracellular pathogen, causes 1.5 million deaths globally. Bacilli Calmette-Guérin (BCG) is commonly administered to protect people against infection; however, there are some obstacles with this first-generation vaccine.
View Article and Find Full Text PDFImproved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
Vaccine
April 2013
Center for Vaccinology, Ghent University Hospital, Ghent, Belgium.
Background: The Bacille Calmette-Guérin (BCG) tuberculosis (TB) vaccine provides incomplete protection, necessitating development of an effective vaccine against TB disease. The Mtb72F/AS02 candidate vaccine was previously shown to be clinically well tolerated and immunogenic in Purified Protein Derivative (PPD)-negative adults. To improve the stability of Mtb72F, a point mutation was introduced into a putative serine protease site to give the final M72 construct.
View Article and Find Full Text PDFDefined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.
Proc Natl Acad Sci U S A
February 2009
Corixa Corporation, Seattle, WA 98104, USA.
Article Synopsis
- - The study investigated the Mtb72F vaccine combined with the AS02A adjuvant in cynomolgus monkeys, showing it to be immunogenic without causing adverse effects.
- - When monkeys previously immunized with BCG received the Mtb72F boost, they demonstrated better protection against tuberculosis compared to those only given BCG, with improvements noted in health and disease outcome.
- - This research is significant as it presents the first evidence of a vaccine enhancing long-term immunity against tuberculosis in monkeys, with important changes in immune response markers linked to improved survival rates.
Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis.
Infect Immun
April 2006
Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA.
Using a rabbit model of tuberculous meningitis, we evaluated the protective efficacy of vaccination with the recombinant polyprotein Mtb72F, which is formulated in two alternative adjuvants, AS02A and AS01B, and compared this to vaccination with Mycobacterium bovis bacillus Calmette-Guérin (BCG) alone or as a BCG prime/Mtb72F-boost regimen. Vaccination with Mtb72F formulated in AS02A (Mtb72F+AS02A) or Mtb72F formulated in AS01B (Mtb72F+AS01B) was protective against central nervous system (CNS) challenge with Mycobacterium tuberculosis H37Rv to an extent comparable to that of vaccination with BCG. Similar accelerated clearances of bacilli from the cerebrospinal fluid, reduced leukocytosis, and less pathology of the brain and lungs were noted.
View Article and Find Full Text PDFThe protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
Infect Immun
November 2004
Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins 80523, USA.
A tuberculosis vaccine candidate consisting of a 72-kDa polyprotein or fusion protein based upon the Mtb32 and Mtb39 antigens of Mycobacterium tuberculosis and designated Mtb72F was tested for its protective capacity as a potential adjunct to the Mycobacterium bovis BCG vaccine in the mouse and guinea pig models of this disease. Formulation of recombinant Mtb72F (rMtb72F) in an AS02A adjuvant enhanced the Th1 response to BCG in mice but did not further reduce the bacterial load in the lungs after aerosol challenge infection. In the more stringent guinea pig disease model, rMtb72F delivered by coadministration with BCG vaccination significantly improved the survival of these animals compared to BCG alone, with some animals still alive and healthy in their appearance at >100 weeks post-aerosol challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!